5 Drugs Stocks Moving The Industry Upward

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 31 points (0.2%) at 15,006 as of Tuesday, July 2, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,611 issues advancing vs. 1,325 declining with 103 unchanged.

The Drugs industry currently sits up 0.4% versus the S&P 500, which is up 0.4%. Top gainers within the industry include Shire ( SHPG), up 1.3%, and GlaxoSmithKline ( GSK), up 0.5%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Valeant Pharmaceuticals International ( VRX) is one of the companies pushing the Drugs industry higher today. As of noon trading, Valeant Pharmaceuticals International is up $0.56 (0.6%) to $88.56 on average volume. Thus far, 738,861 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $88.07-$89.37 after having opened the day at $89.25 as compared to the previous trading day's close of $88.00.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $28.6 billion and is part of the health care sector. Shares are up 47.2% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Eli Lilly and Company ( LLY) is up $0.44 (0.9%) to $50.60 on average volume. Thus far, 3.1 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5.3 million shares. The stock has ranged in price between $50.07-$50.93 after having opened the day at $50.08 as compared to the previous trading day's close of $50.16.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $55.3 billion and is part of the health care sector. The company has a P/E ratio of 11.9, below the S&P 500 P/E ratio of 17.7. Shares are down 0.4% year to date as of the close of trading on Monday. Currently there are 6 analysts that rate Eli Lilly and Company a buy, 3 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, largely solid financial position with reasonable debt levels by most measures, notable return on equity and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Eli Lilly and Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Celgene Corporation ( CELG) is up $2.00 (1.7%) to $120.91 on average volume. Thus far, 1.2 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.1 million shares. The stock has ranged in price between $118.93-$120.99 after having opened the day at $119.00 as compared to the previous trading day's close of $118.91.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $48.8 billion and is part of the health care sector. The company has a P/E ratio of 35.6, above the S&P 500 P/E ratio of 17.7. Shares are up 51.5% year to date as of the close of trading on Monday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Gilead ( GILD) is up $0.76 (1.5%) to $52.41 on light volume. Thus far, 3.6 million shares of Gilead exchanged hands as compared to its average daily volume of 12.1 million shares. The stock has ranged in price between $51.42-$52.49 after having opened the day at $51.70 as compared to the previous trading day's close of $51.66.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $78.2 billion and is part of the health care sector. The company has a P/E ratio of 28.5, above the S&P 500 P/E ratio of 17.7. Shares are up 39.6% year to date as of the close of trading on Monday. Currently there are 20 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, solid stock price performance, reasonable valuation levels and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Merck ( MRK) is up $0.24 (0.5%) to $46.56 on light volume. Thus far, 4.0 million shares of Merck exchanged hands as compared to its average daily volume of 18.9 million shares. The stock has ranged in price between $46.03-$46.73 after having opened the day at $46.27 as compared to the previous trading day's close of $46.32.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $140.3 billion and is part of the health care sector. The company has a P/E ratio of 24.1, above the S&P 500 P/E ratio of 17.7. Shares are up 13.1% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Merck a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

UK GDP Hits Slowest Pace in Five Years as Cold Snap Hammers Construction

UK GDP Hits Slowest Pace in Five Years as Cold Snap Hammers Construction

Amazon Shares on Record Path, Challenging Apple as World's Biggest Company

Amazon Shares on Record Path, Challenging Apple as World's Biggest Company

Global Stocks Rise on Tech Resurgence; Dollar Past 3-Month High Ahead of Q1 GDP

Global Stocks Rise on Tech Resurgence; Dollar Past 3-Month High Ahead of Q1 GDP

Daimler Shares Rise After Record Mercedes-Benz Sales, Bullish Profit Outlook

Daimler Shares Rise After Record Mercedes-Benz Sales, Bullish Profit Outlook

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI